TY - JOUR
T1 - Efficacy of anthiyperglycemic therapies and the influence of baseline hemoglobin A1C
T2 - A meta-analysis of the liraglutide development program
AU - Henry, Robert
AU - Buse, John
AU - Sesti, Giorgio
AU - Davies, Melanie
AU - Jensen, Klaus
AU - Brett, Jason
AU - Pratley, Richard
PY - 2011/11/1
Y1 - 2011/11/1
N2 - Objective: To compare liraglutide versus common antihyperglycemic treatments in reducing hemoglobin A1c (A1C) values across multiple levels of baseline glycemic control and in reaching glycemic targets. Methods: Pooled patient data from 7 phase 3, multinational, randomized controlled trials in patients with type 2 diabetes were stratified by baseline A1c values into 5 categories: 7.5%, >7.5% to 8.0%, >8.0% to 8.5%, >8.5% to 9.0%, and y9.0%. The changes in A1c from baseline to week 26 of treatment and patient proportions reaching A1c targets of <7.0% and 6.5% were compared between liraglutide (1.8 mg daily) and sitagliptin, glimepiride, rosiglit-azone, exenatide, and insulin glargine across all baseline A1c categories.Results: Irrespective of treatment, reductions in A1c levels were generally greater in groups with higher baseline A1c values. After 26 weeks of treatment, liraglutide produced the greatest reductions in A1c values across all baseline categories, ranging from 0.7% to 1.8% (baseline A1c categories 7.5% to >9.0%, respectively), followed by insulin glargine (0.3% to 1.5%) and then by glimepiride (0.4% to 1.3%). Generally, larger percentages of patients achieved the A1c target of 6.5% with liraglutide therapy across all baseline categories (from 62% of patients with A1c values 7.5% to 10% of patients with A1c values >9.0%) in comparison with other treatments (ranging from 49% to 0% of patients, respectively). Similarly, greater proportions of patients also reached the A1c target of <7.0% with liraglutide therapy across all baseline categories (from 83% of patients with A1c values 7.5% to 25% of patients with A1c values >9.0%) versus comparators (from 74% to 5% of patients, respectively). Conclusion: Across a wide spectrum of baseline A1c categories, liraglutide is an efficacious treatment option for patients with type 2 diabetes.
AB - Objective: To compare liraglutide versus common antihyperglycemic treatments in reducing hemoglobin A1c (A1C) values across multiple levels of baseline glycemic control and in reaching glycemic targets. Methods: Pooled patient data from 7 phase 3, multinational, randomized controlled trials in patients with type 2 diabetes were stratified by baseline A1c values into 5 categories: 7.5%, >7.5% to 8.0%, >8.0% to 8.5%, >8.5% to 9.0%, and y9.0%. The changes in A1c from baseline to week 26 of treatment and patient proportions reaching A1c targets of <7.0% and 6.5% were compared between liraglutide (1.8 mg daily) and sitagliptin, glimepiride, rosiglit-azone, exenatide, and insulin glargine across all baseline A1c categories.Results: Irrespective of treatment, reductions in A1c levels were generally greater in groups with higher baseline A1c values. After 26 weeks of treatment, liraglutide produced the greatest reductions in A1c values across all baseline categories, ranging from 0.7% to 1.8% (baseline A1c categories 7.5% to >9.0%, respectively), followed by insulin glargine (0.3% to 1.5%) and then by glimepiride (0.4% to 1.3%). Generally, larger percentages of patients achieved the A1c target of 6.5% with liraglutide therapy across all baseline categories (from 62% of patients with A1c values 7.5% to 10% of patients with A1c values >9.0%) in comparison with other treatments (ranging from 49% to 0% of patients, respectively). Similarly, greater proportions of patients also reached the A1c target of <7.0% with liraglutide therapy across all baseline categories (from 83% of patients with A1c values 7.5% to 25% of patients with A1c values >9.0%) versus comparators (from 74% to 5% of patients, respectively). Conclusion: Across a wide spectrum of baseline A1c categories, liraglutide is an efficacious treatment option for patients with type 2 diabetes.
UR - http://www.scopus.com/inward/record.url?scp=84855829644&partnerID=8YFLogxK
U2 - 10.4158/EP.17.6.906
DO - 10.4158/EP.17.6.906
M3 - Article
C2 - 22193143
AN - SCOPUS:84855829644
SN - 1530-891X
VL - 17
SP - 906
EP - 913
JO - Endocrine Practice
JF - Endocrine Practice
IS - 6
ER -